Platinum compounds having a heterocycle ligand, nanoparticles, and uses thereof
The present disclosure relates to novel platinum compositions having a heterocycle ligand and nanoparticles and methods using such compositions, e.g. for treating cancer.
1. A compound of Formula I,
wherein:
X is a halide, carboxylate, carbonate, carbamate, sulfonate, sulfate, or phosphate;
L is amine or substituted amine;
Y is selected from Nitrogen, Phosphorus, Oxygen and Sulfur;
A together with Y form a heteroaromatic optionally substituted with one or more substituents each independently selected from halogen, cyano, nitro, hydroxyl, ester, ether, alkoxy, aryloxy, amino, amide, carbamate, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heterocyclyl, phosphono, phosphate, sulfide, sulfinyl, sulfino, sulfonyl, sulfo, and sulfonamide, wherein each of the ester, ether, alkoxy, aryloxy, amino, amide, carbamate, alkyl, alkenyl, alkynyl, aryl, arylalky, cycloalkyl, heteroaryl, heterocyclyl, phosphono, phosphate, sulfide, sulfinyl, sulfino, sulfonyl, sulfo, and sulfonamide is optionally substituted with one or more suitable substituents; and
wherein X and L form a bidentate ligand, or
A together with Y or X form a bidentate ligand; and
R 1 and R 2 are each independently H, alkyl, aryl and heteroaryl wherein each of said alkyl, aryl and heteroaryl is optionally substituted with one or more suitable substituents, or R 1 and R 2 may be joined together with the nitrogen to form a 3- to 12-membered ring wherein the 3- to 12-membered ring is optionally substituted with one or more suitable substituents;
wherein X and L form a hidentate ligand, or
A together with Y or X form a bidentate ligand.
2. The compound of claim 1 , wherein each X is independently selected from the group consisting of carbamate and carboxylate.
3. The compound of claim 1 , wherein X is —O(C═O)R a or is —O(C═O)—N—(R a )(R b ); wherein R a and R b are hydrogen, alkyl, aryl, arylalkyl, or cycloalkyl, or cycloalkyl, wherein each of the alkyl, aryl, arylalkyl, and cycloalkyl is optionally substituted with one or more suitable substituents.
4. The compound of claim 1 , wherein L is an amine.
5. The compound of claim 4 , wherein L is a substituted amine.
6. The compound of claim 1 , wherein Y is N.
7. The compound of claim 1 , wherein the heteroaromatic is selected from a monocyclic heteroaromatic, a bicyclic heteroaromatic, or a tricyclic heteroaromatic.
8. The compound of claim 1 having Formula II:
Wherein R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 each is independently selected from hydrogen, halogen, cyan, nitro, hydroxyl, ester, ether, alkoxy, aryloxy, amino, amide, carbamate, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heterocyclyl, phosphono, phosphate, sulfide, sulfinyl, sulfino, sulfonyl, sulfo, and sulfonamide, wherein each of the ester, ether, alkoxy, aryloxy, amino, amide, carbamate, alkyl, alkenyl, alkynyl, aryl, arylalkyl, cycloalkyl, heteroaryl, heterocyclyl, phosphono, phosphate, sulfide, sulfonyl, sulfino, sulfonyl, sulfo, and sulfonamide is optionally substituted with one or more suitable substituents; or optionally, two adjacent substituents selected from R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , and R 11 are connected to form an optionally substituted 5 or 6-membered ring; and
L, X, and Z are as defined herein.
9. A compound selected from a group consisting of:
10. A pharmaceutical composition comprising a compound from claim 1 .